Eisai Clinical Trials
Study Overview
E7766
E7766
NCT04144140, 2019-000160-17
Feb 2020 - Jul 2022
Advanced Solid Tumors or Lymphomas
1. Dose Escalation Part: Number of Participants With Dose-limiting Toxicities (DLTs) [Time Frame: Cycle 1 (Cycle length= 21 days)]
2. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) [Time Frame: From the first dose of the study drug up to 90 days after the last dose (up to 9 months and 14 days)]
3. Dose Expansion Part: Objective Response Rate Based on Modified Response Evaluation Criteria In Solid Tumors (mRECIST) v1.1 [Time Frame: From date of first dose of study drug until confirmed CR or PR (up to 29 months)]
2. Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) [Time Frame: From the first dose of the study drug up to 90 days after the last dose (up to 9 months and 14 days)]
3. Dose Expansion Part: Objective Response Rate Based on Modified Response Evaluation Criteria In Solid Tumors (mRECIST) v1.1 [Time Frame: From date of first dose of study drug until confirmed CR or PR (up to 29 months)]
-
Males and females 18 Years and older (Adult, Older Adult)
-
Completed -
Phase 1
France, Korea, Republic of, Spain, United Kingdom, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR